Chronic Schizophrenia
Conditions
Keywords
Schizophrenia, Cognitive Remediation, Working abilities and social functioning
Brief summary
This study, driven on schizophrenic patients, is aimed at : 1. Measuring the efficiency of the cognitive remediation program RECOS (COgnitive REmediation in Schizophrenia) on the capacity of the patients suffering from schizophrenia to improve the integration in sheltered employment (ESAT and EA). 2. Comparing the efficiency of the program of cognitive remediation RECOS (RECOS arm) to the one of an usual program of coverage/care (TAU arm = Treatment As Usual) on integration in sheltered employment of patients suffering from schizophrenia. 3. Realizing a comparative analysis, in both arms, of : 1. the number of working hours achieved in sheltered environment during the 6 months following the two programs (reported to the working time planned by the contract of employment) 2. the duration of such employments in sheltered areas. 4. Estimating the impact of RECOS on the neuropsychological variables, the symptomatology, the consciousness of the disorders(insight), the quality of life and the social autonomy before the treatment (month M0), at the end of the treatment (month M3), and 6 months later (month M9), and looking for a correlation between the improvement of these parameters and sheltered employment. 5. Estimating the impact of cognitive remediation on integration in sheltered employment.
Interventions
BEHAVIORALRECOS (COgnitive REmediation for Schizophrenia)
Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours. After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9). In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9).
BEHAVIORALTAU (Treatment As Usual)
The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed. In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9).
Sponsors
Sainte Anne Hospital (Paris)
Clermont-de-l'Oise Hospital (Clermont-de-l'Oise)
Saint-Egrève Hospital (Saint-Egrève)
Centre Hospitalier de Niort
Sainte-Marguerite Hospital (Marseille)
Centre Hospitalier Henri Laborit
University Hospital, Tours
Mental Health Center MGEN (Rueil-Malmaison)
Nantes University Hospital
Mental Health Center MGEN (Lille)
Hôpital le Vinatier
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Age from 18 to 50 years. * Schizophrenia according to the criteria of the DSM-IV-TR. * Project of entry to ESAT or to EA in the 6 weeks which follow. * IQ \> 70 (F-NART). * Stable symptomatology during the month preceding the inclusion. * Psychotropic treatment unchanged during the month preceding the inclusion (change no more than 25 % posology). * Overdrawn performances in at least one of the 6 functions estimated by the kit of neuropsychological tests. * French mother tongue. * Informed and signed consent by the patient. * Agreement of the guardian (for protected adults). * Membership in a national insurance scheme.
Exclusion criteria
* Dependence and recent abuses of cannabis (\> 2 / week) or in any other substance (according to the criteria of the DSM-IV-TR), except tobacco. * Neurological disorders of vascular, infectious or neurodegenerative origin; dyschromatopsie. * Taking of medicine with somatic tropism having a cerebral or psychic impact (eg: corticoids). * Simultaneous participation to any other program of remediation targeting the neurocognitive deficits. * Resistance to neuroleptic. * Reading and writing not acquired.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of worked hours during the first 6 months of the contract of employment | Outcome measures are daily assessed during 6 months (M4 to M9) | Compared evolution in both arms (RECOS and TAU) of the number of worked hours, with regard to the number of hours planned in the contract of employment, during the 6 months following the entry in sheltered working environment (i.e. an external, validated and strong measure of the capacity of the patient to fit professionally). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compared evolution of the neuropsychological and clinical balance sheets between the beginning and the end of the Cognitive Remediation period (or the end of the Treatment As Usual period for the TAU arm) | Scores are assessed 3 times: at M0 (Inclusion), at M3 (after Cognitive Remediation or Treatment As Usual), and at M9 (6 month after end of treatment). | Compared evolution, in both arms (RECOS and TAU) of the scores obtained in the different neuropsychological tests, and in the scales of clinical symptomatology (PANSS, questionnaires of insight, self-respect, well being, social autonomy, and cognitive complaint) at the moment of the inclusion (month M0), early after the training period of Cognitive Remediation or Treatment as Usual (M3), and 6 month after (M9). |
| Compared evolution of the neuropsychological and clinical balance sheets during the 6 first months of working contract (i.e. following the end of the training Cognitive Remediation period or after the Treatment As Usual period for the TAU arm). | Neuropsychological and clinical scores are assessed twice : at M3 (after Cognitive Remediation or Treatment As Usual), and at M9 (after 6 months of working period). Occupational integration (EATR) is assessed twice at the same moments (M3 & M9). | Compared evolution, in both arms (RECOS and TAU) of the scores obtained in the different neuropsychological tests, and in the scales of occupational integration (EATR), clinical symptomatology (PANSS, questionnaires of insight, self-respect, well being, social autonomy, and cognitive complaint) after the training period of Remediation and at the moment of the entry in sheltered working environment (month M3), and 6 months later (month M9). |
Countries
France
Outcome results
None listed